Switching to Duloxetine From Selective Serotonin Reuptake Inhibitor Antidepressants: A Multicenter Trial Comparing 2 Switching Techniques
The DOI matches its Crossref record.
Abstract
Article AbstractObjective: To compare 2 methods of switching selective serotonin reuptake inhibitor (SSRI) nonresponders or partial responders to duloxetine. Method: Adult outpatients with DSM-IV major depressive disorder, a Hamilton Rating Scale for Depression (HAM-D17) total score of >= 15, and a Clinical Global Impressions-Severity of Illness score of >= 3 despite at least 6 weeks of SSRI treatment were randomly assigned to either abrupt discontinuation of SSRI immediately followed by initiation of duloxetine (direct switch ; N = 183) or tapered discontinuation of SSRI over 2 weeks and simultaneous administration of duloxetine (start-taper switch ; N = 185). Efficacy, safety, and tolerability outcomes associated with these 2 switch methods were compared following switch and after 10 weeks of duloxetine treatment. The study was conducted from August 2004 to March 2006. Results: There was a significant improvement in depressive symptom severity in both switch groups as measured by mean change in HAM-D17 total score (p <= .001), but no difference between the switch groups (-10.23 DS vs. -10.49 STS). Criteria for noninferiority of the DS group to the STS group, which was the primary objective of the study, were met. Response rates (54.4% DS vs. 59.6% STS), remission rates (35.7% DS vs. 37.2% STS), and other secondary outcome measures were similar for both switch groups. Few patients discontinued the study due to adverse events (6.6% DS vs. 3.8% STS). Headache, dry mouth, and nausea were the most frequently reported adverse events in both switch groups. Conclusions: Switch to duloxetine was associated with significant improvements in both emotional and painful physical symptoms of depression and was well tolerated and safe, regardless of which of the switch methods was used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Arakawa, R., Stenkrona, P., Takano, A., Svensson, J., Andersson, M., Nag, S., Asami, Y., Hirano, Y., Halldin, C., & Lundberg, J. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz003 · Cited by 70
“Also, MDD patients who failed to respond to SSRIs have been shown to improve when switched to serotonin and norepinephrine reuptake inhibitors (SNRIs), which have dual-target sites including 5-HTT and NET (Papakostas et al., 2008; Perahia et al., 2008).”
BackgroundPerahia, D. G. S., Quail, D., Desaiah, D., Montejo, A. L., & Schatzberg, A. F. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.07.001 · Cited by 64
Self-citationGuidance for the discontinuation or switching of antidepressant therapies in adults
Ogle, N. R., & Akkerman, S. R. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190012467210 · Cited by 45
Florea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B., & Abetz-Webb, L. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.008 · Cited by 35
Metadata
- Authors
- Perahia, D. G. S., Quail, D., Desaiah, D., Corruble, E., & Fava, M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-01-15
- Volume
- 69
- Issue
- 1
- Pages
- 95-105
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2018996828
- Cited by
- 46
- References
- 0
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Switching to Duloxetine From Selective Serotonin Reuptake Inhibitor Antidepressants: A Multicenter Trial Comparing 2 Switching Techniques. https://app.cochat.ai/papers/10.4088/jcp.v69n0113
- The paper
- Perahia, D. G. S., Quail, D., Desaiah, D., Corruble, E., & Fava, M. (2008). Switching to Duloxetine From Selective Serotonin Reuptake Inhibitor Antidepressants: A Multicenter Trial Comparing 2 Switching Techniques. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v69n0113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.